EGFR and breast carcinoma: The immunohistochemical profile of this tumor consisting of p63 and high weight cytokeratin 5/6, 17 and 14 positivity in the tumor cells along with EGFR immunoreactivity are immunophenotypically compatible with HSMC and a “basal-like breast carcinoma” or “core basal” phenotype as defined by the Neilson Criteria [14].